Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment-Reference-Cited by-同舟云学术

Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment

Published:2017-01-31 Issue:11 Volume:47 Page:1127-1136
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Suda Goki¹,Nagasaka Atsushi²,Yamamoto Yoshiya³,Furuya Ken⁴,Kumagai Kenichi⁵,Kudo Mineo⁶,Terashita Katsumi¹⁷,Kobayashi Tomoe¹⁸,Tsunematsu Izumi⁹,Yoshida Junichi¹⁰,Meguro Takashi¹¹,Kimura Megumi¹,Ito Jun¹,Umemura Machiko¹,Izumi Takaaki¹,Tsunematsu Seiji¹,Sato Fumiyuki¹,Tsukuda Yoko¹²,Nakai Masato¹,Sho Takuya¹,Natsuizaka Mitsuteru¹,Morikawa Kenichi¹^ORCID,Ogawa Koji¹,Sakamoto Naoya¹,

Affiliation:

1. Department of Gastroenterology and Hepatology, Graduate School of Medicine; Hokkaido University; Sapporo Japan

2. Department of Gastroenterology and Hepatology; Sapporo City General Hospital; Sapporo Japan

3. Department of Gastroenterology and Hepatology; Hakodate City General Hospital; Hakodate Japan

4. Department of Gastroenterology and Hepatology; JCHO Hokkaido Hospital; Sapporo Japan

5. Department of Gastroenterology and Hepatology; Hakodate Medical Association Hospital; Hakodate Japan

6. Department of Gastroenterology and Hepatology; Sapporo Hokuyu Hospital; Sapporo Japan

7. Department of Gastroenterology and Hepatology; Kushiro Rosai Hospital; Kushiro Japan

8. Department of Gastroenterology and Hepatology; Tomakomai City Hospital; Tomakomai Japan

9. Department of Gastroenterology and Hepatology; Touei Hospital; Sapporo Japan

10. Department of Gastroenterology and Hepatology; JCHO Sapporo Hokushin Hospital

11. Department of Gastroenterology and Hepatology; Hokkaido Gastroenterology Hospital; Sapporo Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hepr.12851/fullpdf

Reference34 articles.

1. Global epidemiology and genotype distribution of the hepatitis C virus infection;Gower;J Hepatol,2014

2. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial;Omata;J Viral Hepat,2014

3. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial;Mizokami;Lancet Infect Dis,2015

4. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection;Kumada;Hepatology,2014

5. Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients;Chayama;Hepatology,2015

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Misunderstanding of hepatitis C virus (HCV) infection status by non–specialized medical doctors in patients who achieved sustained virologic response to anti-HCV therapy;Journal of Infection and Chemotherapy;2022-09

2. Hepatitis C Virus Infection in Pregnancy and Children: Its Implications and Treatment Considerations with Directly Acting Antivirals: A Review;Journal of Nepal Medical Association;2021-09-11

3. Changes in the estimated renal function after hepatitis C virus eradication with direct‐acting antiviral agents: Impact of changes in skeletal muscle mass;Journal of Viral Hepatitis;2021-02-24

4. Development of interferon-free, direct-acting antivirals treatment for Japanese patients with chronic hepatitis C infection and chronic kidney disease;Journal of Nippon Medical School;2021

5. Tenofovir–disoproxil–fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection;Journal of Gastroenterology;2020-11-19